21 U.S.C. § 114 to 114d–1
Repealed. Pub. L. 107–171, title X, § 10418(a)(8), (9), May 13, 2002, 116 Stat. 508
Exact citation match for 21 USC § 114-114D-1
Search
Search by citation or keyword across the current edition within Title 21.
Repealed. Pub. L. 107–171, title X, § 10418(a)(8), (9), May 13, 2002, 116 Stat. 508
Exact citation match for 21 USC § 114-114D-1
Repealed. Pub. L. 106–554, § 1(a)(1) [title V, § 517], Dec. 21, 2000, 114 Stat. 2763, 2763A–73
Repealed. Pub. L. 106–554, § 1(a)(1) [title V, § 517], Dec. 21, 2000, 114 Stat. 2763, 2763A–73
Repealed. Pub. L. 106–185, § 2(c)(3), Apr. 25, 2000, 114 Stat. 210
Repealed. Pub. L. 106–185, § 2(c)(3), Apr. 25, 2000, 114 Stat. 210
Repealed. Pub. L. 107–171, title X, § 10418(a)(1), (8), (16), May 13, 2002, 116 Stat. 507, 508
Repealed. Pub. L. 107–171, title X, § 10418(a)(1), (8), (16), May 13, 2002, 116 Stat. 507, 508
Inapplicability of drug fees to designated medical gases
Inapplicability of drug fees to designated medical gases
Recognition of foreign government inspections
Recognition of foreign government inspections
Food and Drug Administration Intercenter Institutes
Food and Drug Administration Intercenter Institutes
Possession, manufacture, or distribution of controlled substance
Possession, manufacture, or distribution of controlled substance
Accelerated approval of priority countermeasures
Accelerated approval of priority countermeasures
Standards for regenerative medicine and regenerative advanced therapies
Standards for regenerative medicine and regenerative advanced therapies
Agency documentation and review of significant decisions regarding devices
Agency documentation and review of significant decisions regarding devices
Program to improve the device recall system
Program to improve the device recall system
Priority review for qualified infectious disease products
Priority review for qualified infectious disease products
Expanded access policy required for investigational drugs
Expanded access policy required for investigational drugs